Stephen G. Dilly
2017 - Aimmune Therapeutics
In 2017, Stephen G. Dilly earned a total compensation of $7.1M as Chief Executive Officer at Aimmune Therapeutics, a 113% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $291,060 |
|---|---|
| Option Awards | $6,325,029 |
| Salary | $490,000 |
| Total | $7,106,089 |
Dilly received $6.3M in option awards, accounting for 89% of the total pay in 2017.
Dilly also received $291.1K in non-equity incentive plan and $490K in salary.
Rankings
In 2017, Stephen G. Dilly's compensation ranked 1,139th out of 14,666 executives tracked by ExecPay. In other words, Dilly earned more than 92.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,139 out of 14,666 | 92nd |
Division Manufacturing | 381 out of 5,770 | 93rd |
Major group Chemicals And Allied Products | 101 out of 2,074 | 95th |
Industry group Drugs | 68 out of 1,730 | 96th |
Industry Pharmaceutical Preparations | 55 out of 1,329 | 96th |
Source: SEC filing on April 11, 2018.
Dilly's colleagues
We found five more compensation records of executives who worked with Stephen G. Dilly at Aimmune Therapeutics in 2017.
2017
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
2017
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
2017
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2017
Jeffrey Knapp
Aimmune Therapeutics
Chief Operating Officer
2017
Warren DeSouza
Aimmune Therapeutics